December 10, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On November 13, 2019, and pursuant to 18 V.S.A. § 4637(b), Teva Pharmaceuticals USA, Inc. ("Teva") submitted a new drug introduction notice for the following (collectively, the "Product"):

NDC #	Product	WAC	Commercial Launch Date
63459-0103-10	TRUXIMA® (rituximab-abbs) 100 MG / 10 ML	$845.55	11/11/2019
63459-0104-50	TRUXIMA® (rituximab-abbs) 500 MG / 50 ML	$ 4,227.75	11/11/2019

Teva now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

1. **US and international marketing and pricing plans used at launch:** Teva declines to provide further information in accordance with 18 V.S.A. § 4637(d).

2. **Estimated volume of patients:** Average of approximately 132 patients per month based on IQVIA data.

3. **Whether the FDA granted breakthrough therapy designation or a priority review:** Neither

4. **For drugs acquired:** Teva acquired rights on October 4, 2016 from Celltrion to commercialize TRUXIMA and another biosimilar product for $160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the TRUXIMA rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights.

*** * * ***

Teva provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this report, Teva does not waive any rights that it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and affiliates, expressly reserves all such rights.

Sincerely,

DocuSigned by:
Katie Hiett
A9CAB028546F4BF...

Katie Hiett
SVP, Strategic Pricing, Contracting & Customer Operations
Teva Pharmaceuticals USA, Inc.